Key Insights

Highlights

Treatment Research

1 treatments under study, led by Dupilumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Not Yet Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07892443Not Yet Recruiting

Type 2 Inflammation in Adults With Cystic Fibrosis

NCT04776694UnknownPrimary

Compassionate Use or Expanded Access of Dupilumab

Showing all 2 trials

Research Network

Common Treatments

  • Dupilumab1

Active Sponsors

  • Regeneron Pharmaceuticals1
  • National Heart Lung And Blood Institute Nhlbi1
  • University Of Virginia1

Related Conditions

  • Cystic Fibrosis Cf1

Activity Timeline